Abstract: Chemotherapy-induced nausea and vomiting (CINV) affects many cancer patients and has a great influence on quality of life. CINV involves coordination of several organs of the gastrointestinal tract, the peripheral and central nervous systems. Many neurotransmitters are involved in this process, and the predominant receptors are serotonin, neurokinin-1 and dopamine receptors. Risk factors for CINV include patient gender and age, past history of CINV, plus the emetogenicity and administration schedule of chemotherapy. Recommended antiemetic regimens for highly emetogenic chemotherapy and moderately emetogenic chemotherapy with a high risk of delayed CINV include a serotonin antagonist, dexamethasone and aprepitant. Other moderately emetogenic chemotherapy requires a serotonin antagonist and dexamethasone. Medications for breakthrough symptoms include dopamine antagonists, lorazepam, metoclopramide, haloperidol, droperidol and other agents. Options for treatment of refractory CINV include olanzapine, dronabinol, nabilone, gabapentin. New evidence from non-controlled studies supports the use of olanzapine, casopitant and gabapentin in controlling the symptoms of CINV.
G astrointestinal (GI) side effects such as nausea and vomiting are common adverse effects from many cancer chemotherapy regimens. Having uncontrolled nausea and vomiting still remains one of the greatest fears of patients undergoing therapy for cancer. Symptoms can range from mild queasiness to violent, repetitive vomiting and retching. Uncontrolled nausea and vomiting can lead to physical effects such as dehydration, electrolyte abnormalities, malnutrition, gastrointestinal tears and bleeding, wound dehiscence, and aspiration pneumonia. Persistent nausea and vomiting can have an even greater effect on the quality of life of the patient. Effects include decreased morale, and decreased ability of the patient to participate in activities of daily life, work, personal care, or recreational activities. Patients with uncontrolled symptoms are more likely to suffer from depression and fatigue.
There have been substantial advances in antiemetic therapy in the last 2 decades. Research into underlying mechanisms in the pathways triggering nausea and vomiting has led to medications targeting neurotransmitters. The use of these antiemetics in combination can provide complete control of nausea and vomiting in most patients who receive chemotherapy. Highly effective antiemetic therapy has allowed administration of high-dose chemotherapy regimens and has allowed administration of chemotherapy in the ambulatory, outpatient care setting.
PATHOPHYSIOLOGY
Multiple organs and multiple neurotransmitters are involved in the response to emetic triggers. Incoming signals from the chemoreceptor trigger zone, GI tract, cerebral cortex, and other areas are collected in the emetic center in the central nervous system. The vomiting center sends out coordinating signals to effector organs such as the esophagus, stomach, and abdominal muscles to complete the emesis. The predominant neurotransmitter receptors involved in this signaling are serotonin (the 5-hydroxytryptamine type 3 [5HT3]) receptors, neurokinin-1 receptors, and dopamine receptors. Other receptors include corticosteroid, histamine, cannabinoid, acetylcholine, GABAminergic, and opiate receptors. Effective antiemetic therapies target these receptors. Combinations of antiemetics are needed in most situations to target multiple receptors.
Chemotherapy can initiate nausea and vomiting by stimulating the release of neurotransmitters from areas of the GI tract and the chemoreceptor trigger zone. The chemoreceptor trigger zone lies outside the blood-brain barrier and senses potential toxins such as chemotherapy agents. The enterochromaffin cells in the GI tract release serotonin in response to damage from chemotherapy, leading to stimulation of the emetic response. Other areas of the central nervous system such as the limbic system, the vestibular system, or the cerebral cortex can stimulate emesis through states such as pain, depression, vertigo, motion sickness, or conditioned responses (anticipatory nausea and vomiting.) The neurotransmitters involved in these pathways are less well understood.
Not all nausea and vomiting in cancer patients is caused by chemotherapy. Other common causes include radiation treatments, brain metastases, migraine, viral gastroenteritis, urinary tract infections, bowel obstructions, hypercalcemia, uremia, gastroparesis, hyperglycemia, and hyponatremia. Medications such as opiates, antibiotics, antifungals, and many others commonly used in cancer patients can cause nausea and vomiting. It is important to consider these causes, because specific treatments for these conditions will be necessary.
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
Chemotherapy-induced nausea and vomiting (CINV) can be described in different phases. Acute CINV starts within a few hours after chemotherapy administration and can last throughout the first day. Delayed CINV symptoms occur after the acute phase and peak in 2-3 days but can last up to 6 -7 days. Anticipatory nausea and vomiting can occur even before chemotherapy administration in patients who have developed a conditioned response to chemotherapy. Despite the labels given to these phases, the patient experiences the same distressing and disruptive symptoms.
Some patients have a higher risk for developing CINV symptoms. 1,2 Patient-related risk factors for developing acute and delayed symptoms are described in Table 1 . Factors associated with the chemotherapy itself also determine the likelihood of CINV. 1, 3, 4 The most predictive factor is the chemotherapy agent's inherent propensity to cause CINV. Some chemotherapies (eg, cisplatin) cause symptoms in Ͼ90% of patients (not treated with antiemetics) and are labeled as highly emetogenic chemotherapy (HEC). Moderately emetogenic chemotherapy (MEC) (eg, carboplatin) causes CINV in 30%-90% of patients. Chemotherapy medications that cause symptoms in 10%-30% of patients are called low emetogenicity agents (LEC) (eg, paclitaxel.) Other agents (eg, vincristine) cause CINV in Ͻ10% of patients and are called minimally emetogenic chemotherapy agents. Table  2 lists the emetogenicity categories for various chemotherapy agents. Various references differ in the estimation of the emetogenicity categories for some chemotherapy agents. For some chemotherapy medications, the emetogenicity risk depends on the dose.
Other chemotherapy-related factors increase the risk of CINV. Chemotherapy regimens with higher doses and faster infusion times increase the risk of symptoms. CINV symptoms tend to get worse with increasing numbers of cycles. With chemotherapy regimens administered over multiple days, the symptoms peak on about the third to fourth days. In these situations, the delayed CINV symptoms from the first days of chemotherapy overlap with the acute symptoms from the later day's doses. Some chemotherapy medications are more likely to cause delayed CINV symptoms. These include cyclophosphamide, ifosfamide, doxorubicin, epirubicin, cisplatin, and carboplatin. Chemotherapy regimens that include more than of these agents are very likely to cause delayed nausea and vomiting, especially in women.
Most chemotherapy agents are administered in combinations of multiple agents, instead of singly. Estimating the emetogenicity of combinations is difficult. One method estimates the total emetogenicity by mathematically accommodating each of the agents. 5 However, no method has been prospectively validated. The best estimate can be obtained from the primary literature describing the chemotherapy combination. If these data are not readily available, the antiemetic therapy should be geared to the highest emetogenicity of the single chemotherapy agent administered on each day. 1, 4, 6 
SEROTONIN ANTAGONISTS
Serotonin antagonists form the backbone of antiemetic combinations for many situations. There are four available agents, ondansetron, granisetron, dolasetron, and palonosetron. Doses and adverse effects of these agents are listed in Table 3 . A tremendous amount of research has been done for the use of these agents. There is a threshold effect at which receptors are fully blocked when a sufficient dose is given. However, a plateau effect has also been found, at which larger doses are not more effective. As single agents, the serotonin antagonists have a response rate of 60%-80%, but this rate is higher when these drugs used with corticosteroids. 1, 4, [7] [8] [9] Oral forms of serotonin antagonists are as effective as intravenous forms. All of these agents are well tolerated, causing few side effects other than headache. A serotonin antagonist should be included in antiemetic combinations for the acute phase for highly or moderately emetogenic chemotherapy. These agents are more effective in preventing emesis than in preventing nausea. Serotonin antagonists are no more effective than other agents (aprepitant, dexamethasone, or prochlorperazine) in the delayed phase and are not recommended for these situations. 10 -14 Palonosetron, a serotonin antagonist with a long halflife of about 40 hours (compared with 3-9 hours for other serotonin antagonists), is the most recently developed of these agents. In 2 trials in MEC and one trial in HEC, palonosetron was compared with single doses of a comparator agent, either ondansetron or dolasetron, given before a single day of chemotherapy. 14 -16 A complete response was defined by no emesis and no need for rescue antiemetics in the acute or delayed phases. Corticosteroid premedication for the acute phase was allowed but not required in 2 of these trials and not allowed in the other trial. Corticosteroid administration for the delayed phase was not included. By choosing these comparator groups, palonosetron was compared with placebo for the delayed phase. Palonosetron demonstrated equivalent or somewhat higher response rates than those of the comparator agent in the acute and delayed phases. Palonosetron has not been compared with antiemetic regimens containing aprepitant or other more accepted regimens for delayed nausea and vomiting.
In a noncomparative trial, palonosetron was combined with aprepitant and dexamethasone in an antiemetic regimen studied in patients receiving MEC. 17 Although not compared with other serotonin antagonists in a triple regimen, this study described high antiemetic response rates, and this regimen was well tolerated. Because of its long elimination half-life, the U.S. Food and Drug Administration approved labeling for palonosetron does not recommend repeat dosing of palonosetron in the 7 days after premedication before a single chemotherapy administration. Recently every other day palonosetron administration was given before daily cisplatin treatments in a noncomparative study in testicular cancer patients. 18 A dose of 0.25 mg of palonosetron was given intravenously before days 1, 3, and 5 of cisplatin, along with varying doses of dexamethasone. This regimen demonstrated high antiemetic response rates in both the acute and delayed phases. Although this regimen was not compared with other serotonin-containing regimens, it was safe and effective. Multiple dose palonosetron was well tolerated, with headache and constipation being the most frequently observed side effects.
Other serotonin antagonists under development include tropisetron, lerisetron, ramosetron, and others. 19, 20 It is difficult to determine which serotonin antagonist is the most cost effective because acquisition costs can vary 
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between the inpatient and outpatient settings and between different clinics and because costs continue to change. Total treatment costs of different antiemetic regimens should be determined to decide which regimen is preferred.
CORTICOSTEROIDS
Corticosteroids like dexamethasone are potent antiemetics, especially in combination with other agents. The precise antiemetic mechanism of action of corticosteroids is unclear but may involve a reduction of serotonin release or activation of corticosteroid receptors in the central nervous system (CNS). 21 The antiemetic activity of corticosteroids has been well demonstrated in a large number of studies. 21, 22 The complete response rates are about 15%-20% higher when dexamethasone is added to serotonin antagonists. Dexamethasone is effective in prevention of CINV in the acute phase and is particularly active in the delayed phase.
Corticosteroids are sometimes underutilized because of concern regarding the potential adverse effects. 21 Its short term use as an antiemetic is actually well tolerated. The most common CNS side effects include insomnia, jitteriness, and increased appetite. Some patients, especially those with underlying diabetes, will experience hyperglycemia. These patients should be advised to check their blood glucose levels more frequently in the days after dexamethasone administration and treat the hyperglycemia appropriately. Other patients may experience heartburn or other GI distress. Because the antiemetic use of corticosteroids is short term, tapering the dose is rarely needed.
When corticosteroids are used as part of the antineoplastic regimen for lymphoid cancers and myeloma, it is not necessary to add additional dexamethasone as an antiemetic. It is important to withhold corticosteroids if interferon or interleukin-2 is part of the chemotherapy regimen because the corticosteroids could potentially reduce the effectiveness of the cancer treatment.
The most appropriate dexamethasone dose for MEC was explored in a 4-arm study comparing a single 8-mg dose with other regimens using larger and more protracted administration. 23 The larger and longer dexamethasone dosing did not improve the antiemetic efficacy of the regimen over that of the lower dose. So, for MEC, the recommended regimen is a single 8-mg dose before chemotherapy.
In another trial, there was some evidence for a doseresponse relationship in HEC. 24 Prechemotherapy doses ranging from 4 to 20 mg were studied. The higher doses of 12 and 20 mg were superior to the lower 4-and 8-mg doses but were not statistically different from each other, although there was a trend to a higher response rate with the 20-mg dose. Therefore, for HEC a 12-or 20-mg prechemotherapy dose is recommended. However, if aprepitant is included in the antiemetic regimen, the 12-mg dose is recommended because of inhibition of the elimination of dexamethasone by aprepitant (see also the section on aprepitant). 4 Dexamethasone is highly active in preventing delayed nausea and vomiting symptoms and forms the backbone of successful preventive regimens. If dexamethasone is used with aprepitant, the usual dose is 8 mg orally daily for 2-4 days after chemotherapy. If aprepitant is not used, the dose should be increased to 8 mg orally 2 times daily for 2-4 days.
NEUROKININ-1 ANTAGONIST
Aprepitant is the only currently available neurokinin-1 receptor antagonist. Its antiemetic action occurs through inhibition of the action of substance P in the emetic pathways in both the central and peripheral nervous systems. Aprepitant is orally available and is recommended in a dose of 125 mg orally before day 1 of chemotherapy plus 80 mg orally daily on days 2 and 3. Its action is best seen when it is used in combination with a serotonin antagonist and dexamethasone. It is well tolerated. Only mild adverse effects of fatigue, hiccups, headache, and diarrhea are generally seen. [25] [26] [27] [28] The cytochrome P450 3A4 system is responsible for the metabolism of aprepitant. Aprepitant is also an inhibitor and an inducer of 3A4, as well as an inducer of CYP2C9. Because of these effects, aprepitant can cause a number of significant drug interactions. 1, 29, 30 The elimination of dexamethasone and other corticosteroids is reduced, and a dose reduction is needed in most cases. 1,29 -32 However, when the corticosteroid is used as an antineoplastic agent, it is not recommended that the dose be reduced. 4 Through its altering of 3A4 activity, aprepitant has the potential for changing the metabolism of several chemotherapy agents, among them paclitaxel, etoposide, ifosfamide, irinotecan, and many others. The true significance of these potential interactions is unclear because some of these chemotherapy agents were used in the original aprepitant trials. Aprepitant induces the metabolism of warfarin, causing low international normalized ratio values. 33 The international normalized ratio values of patients treated with both warfarin and aprepitant should be monitored carefully and the warfarin dose adjusted appropriately. In addition, aprepitant has the potential for interacting with other medications such as phenytoin, itraconazole, terfenadine, and oral contraceptives. 29, 30, 32 The value of aprepitant in prevention of CINV with HEC was demonstrated in 2 trials with cisplatin-based chemotherapy. 25, 26 Aprepitant was given in the standard dose and was added to ondansetron (given on day 1) and dexamethasone (given on days 1-4.) The patients in the aprepitant arms fared better, with a higher rate of complete antiemetic response in the acute and delayed phases. It seems that aprepitant is even more effective in women than in men. 34 Aprepitant was also studied in the context of MEC administration. 27 All patients received ondansetron and dexamethasone before chemotherapy administration. Patients in the aprepitant arm also received aprepitant in the acute and delayed phases. Patients in the control arm received ondansetron in the delayed phase. Those patients in the aprepitant arm did have a higher complete antiemetic response rate in both the acute and delayed phases. However, aprepitant was not compared with dexamethasone, which is one of the most active agents for delayed CINV symptoms, in the delayed phase.
In another trial in patients receiving HEC, a standard triple-drug aprepitant-containing regimen was compared with a regimen containing ondansetron and dexamethasone in both the acute and delayed phases. 28 The patients in the aprepitant Chemotherapy-Induced Nausea and Vomiting arm had higher complete response rates in both the acute and delayed phases. This study confirmed that an aprepitant/ dexamethasone regimen is a better choice than a serotonin antagonist/dexamethasone combination for preventing delayed CINV symptoms.
DOPAMINE ANTAGONISTS
An older class of antiemetics works primarily through inhibition of dopamine receptors. These include phenothiazines (prochlorperazine and promethazine,) butyrophenones (haloperidol and droperidol), and metoclopramide. The usual doses and adverse effects of these medications are outlined in Table 3 . The routine prophylactic use of these medications has not been common since the advent of the serotonin antagonists. These agents still have use as medications for breakthrough CINV symptoms and as adjunctive medications in building antiemetic regimens for patients with refractory nausea and vomiting. All of these medications cause more sedation and extrapyramidal symptoms and other adverse effects than other antiemetics, which limits their use. However, these agents are useful because they are available in oral as well as parenteral dosage forms.
BENZODIAZEPINES
Lorazepam is widely used as an antiemetic, especially for patients with breakthrough symptoms, but its mechanism of action is poorly understood. It is an effective treatment for anxiety but may also act as an antiemetic by inhibiting impulses from the cerebral cortex to the emetic center in the CNS. Lorazepam causes a variable amount of CNS depression, but many patients tolerate it quite well without excessive sedation. It is a useful addition for patients with insomnia, anxiety, or refractory nausea and vomiting. In addition, treatment with lorazepam can reduce symptoms of anticipatory CINV. Lorazepam can also be administered orally or parenterally. The usual dose and adverse effects of lorazepam are listed in Table 3 .
CANNABINOIDS
Cannabinoid medications can act as antiemetic agents through their effect at cannabinoid receptors in multiple parts of the CNS involved in the emetic response. Cannabinoid receptors also help control the effect of serotonin, dopamine, and other neurotransmitters in these pathways. Cannabinoids may also have an effect at the enterochromaffin cells in the GI tract. Two cannabinoid medications, dronabinol and nabilone, have been approved for CINV. The usual doses of these medications are shown in Table 3 . Although there are conflicting data, [35] [36] [37] cannabinoids can be useful agents for patients who do not have adequate nausea and vomiting control with standard antiemetic regimens. The use of these agents is limited by their substantial adverse effects, which include sedation, dysphoria, vertigo, euphoria, dizziness, and dry mouth. There is a subset of patients who respond very well to cannabinoids and who can tolerate the side effects. In these patients, nabilone and dronabinol should probably be offered as a scheduled medication instead of "as needed" because of their slower onset of action. Table 4 describes recommended antiemetic regimens for different CINV situations. For multiday chemotherapy regimens, the antiemetics should be geared toward the che- motherapy with the highest emetogenicity given on each day. In general, for HEC and MEC, the antiemetic regimen should include both a serotonin antagonist and dexamethasone. Aprepitant should be added for HEC and for MEC that has a high risk of causing delayed nausea and vomiting. Antiemetics for breakthrough symptoms should be provided, and the patient should be encouraged to take these medications before the nausea and vomiting becomes significant. For most patients receiving LEC, no premedication is needed. However, if necessary (ie, a past history of significant CINV), a single dose of a dopamine antagonist or dexamethasone may be offered. No prophylactic antiemetics are needed for minimally emetogenic chemotherapy. Patients suffering from anticipatory nausea and vomiting should be referred for behavioral therapies such as relaxation techniques, hypnosis, and others. If medication is needed, a benzodiazepine, such as lorazepam or alprazolam, can be offered the night before and the morning of chemotherapy treatment.
ANTIEMETIC REGIMENS

NEWER ANTIEMETIC RESEARCH
Although modern antiemetic regimens offer complete protection for most patients, a significant number of patients have residual or refractory CINV. Newer agents are being investigated for activity in preventing nausea and vomiting. Some of these agents are chemically related to currently available agents and other suggest new mechanisms of action.
Olanzapine
Olanzapine is an atypical antipsychotic medication that is usually used to treat mania and schizophrenia. However, it also antagonizes several neurotransmitters involved in the CINV pathways. These include several serotonin (including 5HT3) and dopamine receptors and others including muscarinic, histamine, and adrenergic receptors. The antipsychotic dose range starts at 5-10 mg daily, but can be adjusted upward to 20 mg daily. The usual adverse effects seen with the antipsychotic uses of olanzapine include sleepiness, extrapyramidal effects, insomnia, dizziness, weight gain, and dry mouth.
The activity of olanzapine as an antiemetic was first demonstrated in the hospice/palliative care arena, in patients with advanced cancer and refractory nausea and vomiting. 38 -40 These studies described good effectiveness from olanzapine without excessive sedation.
In a phase I trial, olanzapine was administered to patients receiving HEC and MEC regimens with standard antiemetics. 41 The maximally tolerated dose of olanzapine was 5 mg orally daily for 9 days, starting 2 days before chemotherapy. Most of the patients receiving HEC and all the patients receiving MEC exhibited a complete antiemetic response.
Another study described the retrospective chart review of 28 patients who had received olanzapine for prevention of delayed CINV symptoms. 42 Most of these patients had received HEC or MEC and had received other antiemetics and had a history of CINV symptoms. Olanzapine had been administered in doses from 2.5-5mg daily. These researchers noted a fairly low rate of nausea and vomiting in these highly pretreated patients. The olanzapine was well tolerated, with few side effects seen in these patients.
In a phase II, noncomparative study, 30 patients were treated with olanzapine with a dose of 5 mg daily for 2 days before chemotherapy, followed by 10 mg daily for 4 days. 43 These patients received HEC and MEC and were pretreated with a standard antiemetic regimen consisting of granisetron and dexamethasone. In the acute phase, all patients demonstrated a complete antiemetic response. In the delayed phase, 80% of patients receiving HEC 85% of patients receiving MEC experienced a complete response. Olanzapine was well tolerated in these patients. Nausea was also well controlled.
Olanzapine was also studied in another phase II trial in 40 patients receiving HEC and MEC. 44 All patients were treated with an antiemetic regimen containing palonosetron and dexamethasone on day 1. Olanzapine was given at a dose of 10 mg orally daily for 5 days starting before chemotherapy administration. No other antiemetic agents were given in the delayed phase. For the 8 patients receiving HEC, the complete antiemetic response rate was 100% in the acute phase and 75% in the delayed phase. For the 32 patients receiving HEC, the complete response rate was 97% in the acute phase and 75% in the delayed phase. This antiemetic regimen was well tolerated, but fatigue, drowsiness, and dry mouth were reported. The authors concluded that this three-drug regimen was very effective in controlling CINV symptoms.
Olanzapine appears to be an effective alternative treatment for refractory CINV symptoms and is well tolerated in most patients without excessive sedation. Further studies comparing olanzapine-containing antiemetic regimens with other regimens containing aprepitant in both phases and dexamethasone in the delayed phase will be required before olanzapine can be routinely recommended for prophylactic CINV regimens.
Gabapentin
Gabapentin is an anticonvulsant medication that is active in several seizure disorders and in diabetic neuropathy, postherpetic neuropathy, migraines, and bipolar disorder as well as vasomotor hot flashes. Gabapentin is an analog of ␥-aminobutyric acid, but its mechanism of action involves calcium channels that control neurotransmitter release. The anticonvulsant dose begins with 300 mg orally 3 times daily but can be advanced slowly up to 2400 mg daily. The neuropathic pain dose starts at 100 mg orally three times daily and can be adjusted up to 1800 mg daily. Gabapentin is renally eliminated, and the dose should be adjusted for patients with reduced renal function to lower the chance of CNS adverse effects. The most common adverse effects include sleepiness, dizziness, confusion, tremor, and headache.
In one publication, a group of researchers described the case of a patient with refractory CINV. 45 This patient was given gabapentin in an effort to control her hot flashes and subsequently her persistent nausea and vomiting resolved. This same group of researchers then conducted a noncontrolled trial in 9 patients with breast cancer who had experienced significant nausea with the chemotherapy regimen containing doxorubicin and cyclophosphamide every 3 weeks. A routine antiemetic regimen (containing ondansetron and dexa-methasone) was used, and some of the patients received lorazepam. The gabapentin dose was 300 mg orally every night for 2 days, starting 5 days before chemotherapy. Then gabapentin was continued at 300 mg orally 2 times daily for 2 days and then at 300 mg orally 3 times daily for 6 days. Most of the patients (7 of 9 patients) experienced improvement in their nausea scores in the acute phase. Eight of the 9 patients had reductions in their delayed-phase nausea. Most of the patients experienced a significant reduction, with a median reduction of 3 points on a 7-point nausea scale. The gabapentin treatment was well tolerated, with only 2 patients having mild to moderate sleepiness.
Gabapentin was also studied in another noncontrolled trial in patients receiving HEC and MEC treatments. 46 These 24 patients had experienced moderate to severe CINV symptoms after previous chemotherapy cycles. A standard antiemetic regimen with a 5HT3 antagonist and dexamethasone was given to all patients. Gabapentin was administered at 300 mg orally 2 days before chemotherapy, 300 mg orally 2 times daily 1 day before chemotherapy, and then 300 mg orally 3 times daily for 5 days. In these patients who had significant previous CINV, 58% experienced no emesis and 75% had non/mild nausea in the acute phase. In the delayed phase, 75%-92% had no emesis and 79%-92% had no/mild nausea, depending on the day of the study. The authors concluded that the gabapentin had improved the nausea and vomiting control of these patients. Further research is needed to further delineate the value of gabapentin in preventing CINV symptoms.
Casopitant
Casopitant is an orally available, investigational neurokinin-1 receptor antagonist. Preclinical data suggested that doses of 50 -150 mg might be effective. One group of researchers reported in abstract form the results of a phase II trial in patients receiving HEC with cisplatin. 47 This was a 6-arm study, but all patients received ondansetron on day 1 and dexamethasone on days 1-4. The 493 patients were randomly assigned to groups receiving 50, 100, or 150 mg of casopitant orally daily on days 1-3 or placebo. The last 2 groups received either 150 mg orally on day 1 only or aprepitant (in the usual regimen). The complete antiemetic response rates (over 120 hours) ranged from 76% to 86% in the casopitant arms, 60% in the control arm, and 72% in the aprepitant arm. The authors concluded that casopitant shows activity in reducing CINV in patients receiving HEC.
In another phase II trial, casopitant was studied in 719 patients receiving a variety of MEC treatments. 48 Patients in the first 5 arms received ondansetron (8 mg 2 times daily) days 1-3 and dexamethasone day 1. Patients in these arms also received 50, 100, or 150 mg of casopitant on days 1-3 or 150 mg on day 1 only or placebo. The patients in the latter arm were randomly assigned to ondansetron (16 mg daily) on days 1-3, dexamethasone on day 1, and 150 mg of casopitant on days 1-3. The 120-hour complete response rate ranged from 79% to 85% among the different treatment arms, compared with 70% in the control arm. The acute-phase response rate ranged from 89% to 92% compared with 90% in the control arm. The authors concluded that casopitant shows activity in preventing CINV. Casopitant was well tolerated in both of these preliminary trials. Information about potential drug interactions with casopitant is not available at this time.
CONCLUSION
CINV involves a complex interaction between multiple organs and multiple neurotransmitters. Likewise, multiple antiemetic agents are needed in conjunction to help control nausea and vomiting. With our most effective modern antiemetic regimens, not all patients are completely protected, although they may hesitate to tell their caregivers how they are faring. Continued research is needed to provide the optimal, most cost-effective antiemetic therapy possible.
